Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Follow-Up Questions
Madrigal Pharmaceuticals Inc 的 CEO 是誰？
Mr. Bill Sibold 是 Madrigal Pharmaceuticals Inc 的 President，自 2023 加入公司。
MDGL 股票的價格表現如何？
MDGL 的當前價格為 $421.51，在上個交易日 increased 了 0%。
Madrigal Pharmaceuticals Inc 的主要業務主題或行業是什麼？
Madrigal Pharmaceuticals Inc 屬於 Biotechnology 行業，該板塊是 Health Care
